A股异动丨康希诺(688185.SH)创历史新高 一针疫苗已在国内多地开打
格隆汇5月21日丨康希诺(688185.SH)涨近5%,报593.96元创其上市以来新高;康希诺生物-B(6185.HK)亦涨2.76%。消息称,只打一针的新冠疫苗目前已在北京、上海、天津、浙江、河南、安徽等多地开打。为满足市场需求,一针疫苗的生产厂商康希诺生物日前正在增加产能。国家卫健委新闻发言人米锋20日在国务院联防联控机制发布会上介绍,近期,各地群众踊跃接种新冠病毒疫苗。截至5月19日,全国累计报告接种44951.1万剂次,其中最近8天共接种超过1亿剂次。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.